202 related articles for article (PubMed ID: 33199492)
1. Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer.
Topka S; Steinsnyder Z; Ravichandran V; Tkachuk K; Kemel Y; Bandlamudi C; Winkel Madsen M; Furberg H; Ouerfelli O; Rudin CM; Iyer G; Lipkin SM; Mukherjee S; Solit DB; Berger MF; Bajorin DF; Rosenberg JE; Taylor BS; de Stanchina E; Vijai J; Offit K
Clin Cancer Res; 2021 Apr; 27(7):1997-2010. PubMed ID: 33199492
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer.
Börcsök J; Sztupinszki Z; Bekele R; Gao SP; Diossy M; Samant AS; Dillon KM; Tisza V; Spisák S; Rusz O; Csabai I; Pappot H; Frazier ZJ; Konieczkowski DJ; Liu D; Vasani N; Rodrigues JA; Solit DB; Hoffman-Censits JH; Plimack ER; Rosenberg JE; Lazaro JB; Taplin ME; Iyer G; Brunak S; Lozsa R; Van Allen EM; Szüts D; Mouw KW; Szallasi Z
Clin Cancer Res; 2021 Apr; 27(7):2011-2022. PubMed ID: 33208343
[TBL] [Abstract][Full Text] [Related]
3.
Li Q; Damish AW; Frazier Z; Liu D; Reznichenko E; Kamburov A; Bell A; Zhao H; Jordan EJ; Gao SP; Ma J; Abbosh PH; Bellmunt J; Plimack ER; Lazaro JB; Solit DB; Bajorin D; Rosenberg JE; D'Andrea AD; Riaz N; Van Allen EM; Iyer G; Mouw KW
Clin Cancer Res; 2019 Feb; 25(3):977-988. PubMed ID: 29980530
[TBL] [Abstract][Full Text] [Related]
4. Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.
Prosz A; Duan H; Tisza V; Sahgal P; Topka S; Klus GT; Börcsök J; Sztupinszki Z; Hanlon T; Diossy M; Vizkeleti L; Stormoen DR; Csabai I; Pappot H; Vijai J; Offit K; Ried T; Sethi N; Mouw KW; Spisak S; Pathania S; Szallasi Z
Sci Rep; 2023 Nov; 13(1):20567. PubMed ID: 37996508
[TBL] [Abstract][Full Text] [Related]
5. Persistence of repair proteins at unrepaired DNA damage distinguishes diseases with ERCC2 (XPD) mutations: cancer-prone xeroderma pigmentosum vs. non-cancer-prone trichothiodystrophy.
Boyle J; Ueda T; Oh KS; Imoto K; Tamura D; Jagdeo J; Khan SG; Nadem C; Digiovanna JJ; Kraemer KH
Hum Mutat; 2008 Oct; 29(10):1194-208. PubMed ID: 18470933
[TBL] [Abstract][Full Text] [Related]
6. Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.
Prosz A; Duan H; Tisza V; Sahgal P; Topka S; Klus GT; Börcsök J; Sztupinszki Z; Hanlon T; Diossy M; Vizkeleti L; Stormoen DR; Csabai I; Pappot H; Vijai J; Offit K; Ried T; Sethi N; Mouw KW; Spisak S; Pathania S; Szallasi Z
bioRxiv; 2023 Feb; ():. PubMed ID: 36798363
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents.
Damia G; Imperatori L; Stefanini M; D'Incalci M
Int J Cancer; 1996 Jun; 66(6):779-83. PubMed ID: 8647649
[TBL] [Abstract][Full Text] [Related]
8. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.
Kim J; Mouw KW; Polak P; Braunstein LZ; Kamburov A; Kwiatkowski DJ; Rosenberg JE; Van Allen EM; D'Andrea A; Getz G
Nat Genet; 2016 Jun; 48(6):600-606. PubMed ID: 27111033
[TBL] [Abstract][Full Text] [Related]
9. Uncommon nucleotide excision repair phenotypes revealed by targeted high-throughput sequencing.
Calmels N; Greff G; Obringer C; Kempf N; Gasnier C; Tarabeux J; Miguet M; Baujat G; Bessis D; Bretones P; Cavau A; Digeon B; Doco-Fenzy M; Doray B; Feillet F; Gardeazabal J; Gener B; Julia S; Llano-Rivas I; Mazur A; Michot C; Renaldo-Robin F; Rossi M; Sabouraud P; Keren B; Depienne C; Muller J; Mandel JL; Laugel V
Orphanet J Rare Dis; 2016 Mar; 11():26. PubMed ID: 27004399
[TBL] [Abstract][Full Text] [Related]
10. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells.
Koeppel F; Poindessous V; Lazar V; Raymond E; Sarasin A; Larsen AK
Clin Cancer Res; 2004 Aug; 10(16):5604-13. PubMed ID: 15328203
[TBL] [Abstract][Full Text] [Related]
11. The mutational impact of Illudin S on human cells.
Casimir L; Zimmer S; Racine-Brassard F; Jacques PÉ; Maréchal A
DNA Repair (Amst); 2023 Feb; 122():103433. PubMed ID: 36566616
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of nucleotide excision repair defects between XPD-mutated fibroblasts derived from trichothiodystrophy and xeroderma pigmentosum patients.
Nishiwaki T; Kobayashi N; Iwamoto T; Yamamoto A; Sugiura S; Liu YC; Sarasin A; Okahashi Y; Hirano M; Ueno S; Mori T
DNA Repair (Amst); 2008 Dec; 7(12):1990-8. PubMed ID: 18817897
[TBL] [Abstract][Full Text] [Related]
13. Expansion of the clinical and molecular spectrum of an XPD-related disorder linked to biallelic mutations in ERCC2 gene.
Agolini E; Botta E; Lodi M; Digilio MC; Rinelli M; Bellacchio E; Alesi V; Nardo T; Zambruno G; Orioli D; Alessi I; Boccuto L; Rossi S; Carai A; Colafati GS; Cacchione A; Dallapiccola B; Novelli A; Mastronuzzi A
Clin Genet; 2021 Jun; 99(6):842-848. PubMed ID: 33733458
[TBL] [Abstract][Full Text] [Related]
14. ERCC2/XPD Lys751Gln alter DNA repair efficiency of platinum-induced DNA damage through P53 pathway.
Zhang G; Guan Y; Zhao Y; van der Straaten T; Xiao S; Xue P; Zhu G; Liu Q; Cai Y; Jin C; Yang J; Wu S; Lu X
Chem Biol Interact; 2017 Feb; 263():55-65. PubMed ID: 28027876
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity and overlaps in nucleotide excision repair disorders.
Ferri D; Orioli D; Botta E
Clin Genet; 2020 Jan; 97(1):12-24. PubMed ID: 30919937
[TBL] [Abstract][Full Text] [Related]
16. A Gene Expression Signature to Predict Nucleotide Excision Repair Defects and Novel Therapeutic Approaches.
Wei R; Dai H; Zhang J; Shih DJH; Liang Y; Xiao P; McGrail DJ; Lin SY
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066883
[TBL] [Abstract][Full Text] [Related]
17. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.
Van Allen EM; Mouw KW; Kim P; Iyer G; Wagle N; Al-Ahmadie H; Zhu C; Ostrovnaya I; Kryukov GV; O'Connor KW; Sfakianos J; Garcia-Grossman I; Kim J; Guancial EA; Bambury R; Bahl S; Gupta N; Farlow D; Qu A; Signoretti S; Barletta JA; Reuter V; Boehm J; Lawrence M; Getz G; Kantoff P; Bochner BH; Choueiri TK; Bajorin DF; Solit DB; Gabriel S; D'Andrea A; Garraway LA; Rosenberg JE
Cancer Discov; 2014 Oct; 4(10):1140-53. PubMed ID: 25096233
[TBL] [Abstract][Full Text] [Related]
18. The ERCC2/XPD Lys751Gln polymorphism affects DNA repair of benzo[a]pyrene induced damage, tested in an in vitro model.
Xiao S; Cui S; Lu X; Guan Y; Li D; Liu Q; Cai Y; Jin C; Yang J; Wu S; van der Straaten T
Toxicol In Vitro; 2016 Aug; 34():300-308. PubMed ID: 27139774
[TBL] [Abstract][Full Text] [Related]
19. The DNA damage response network in the treatment of head and neck squamous cell carcinoma.
Psyrri A; Gkotzamanidou M; Papaxoinis G; Krikoni L; Economopoulou P; Kotsantis I; Anastasiou M; Souliotis VL
ESMO Open; 2021 Apr; 6(2):100075. PubMed ID: 33714009
[TBL] [Abstract][Full Text] [Related]
20. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
